Common Stock, $0.01 par value per share
- Symbol
- EXAS
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Historical · closed Mar 23, 2026
Current Report · Items 1.01, 1.02, 2.01, 3.01, 3.03, 5.01, 5.02, 5.03, 9.01 · 8-K
Item 1.01 Entry into a Material Definitive Agreement. Exact has outstanding 0.3750% Convertible Senior Notes due 2027 (the “2027 Notes”), 0.3750% Convertible Senior Notes due 2028 (the “2028 Notes”), 2.00% Convertible Senior Notes due 2030 (the “2030 Notes”) and 1.75% Convertible Senior Notes due 2031 (the “2031 Notes” and, together with the 2027 Notes, the 2028 Notes and the 2030 Notes, the “Notes”).…
Exact Sciences’ Precision Oncology portfolio delivers actionable genomic insights to inform prognosis and cancer treatment after a diagnosis. In breast cancer, the Oncotype DX Breast Recurrence Score® test is the only test shown to predict the likelihood of chemotherapy benefit as well as recurrence in invasive breast cancer. The Oncotype DX test is recognized as the standard of care and is included in all major breast cancer treatment guidelines. The OncoExTra® test applies comprehensive tumor profiling, utilizing whole exome and whole transcriptome sequencing, to aid in therapy selection for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer. With an extensive panel of approximately 20,000 genes and 169 introns, the OncoExTra test is one of the most comprehensive genomic (DNA) and transcriptomic (RNA) panels available today. Exact Sciences enables patients to take a more active role in their cancer care and makes it easy for providers to order tests, interpret results, and personalize medicine, by applying real-world evidence and guideline recommendations. To learn more, visit precisiononcology.exactsciences.com.
EXACT SCIENCES CORP · 8-K · Filed 2026-03-23
EX-4.1 4 d128802dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 SIXTH SUPPLEMENTAL INDENTURE THIS SIXTH SUPPLEMENTAL INDENTURE (this “Sixth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of January 17, 2018 (the “Base Indenture”), and the Second Supplemental Indenture, dated as of March 8, 2019 (the “Second Supplemental Indenture”, together with the Base Indenture, the “2027 Notes Indenture”) providing for the issuance of the 0.3750% Convertible Senior Notes due 2027 (the “Notes”); WHEREAS, the Company entered into that certain Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among the Company, Abbott Laboratories, an Illinois corporation (“Abbott”), and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott (“Merger Sub”), pursuant to which, on the terms and subject to the conditions set forth i…
Open exhibit ↗EX-4.2 5 d128802dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 SEVENTH SUPPLEMENTAL INDENTURE THIS SEVENTH SUPPLEMENTAL INDENTURE (this “Seventh Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association (as successor to U.S. Bank National Association), as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of January 17, 2018 (the “Base Indenture”), and the Third Supplemental Indenture, dated as of February 27, 2020 (the “Third Supplemental Indenture”, together with the Base Indenture, the “2028 Notes Indenture”) providing for the issuance of the 0.3750% Convertible Senior Notes due 2028 (the “Notes”); WHEREAS, the Company entered into that certain Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among the Company, Abbott Laboratories, an Illinois corporation (“Abbott”), and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott (“Merger Sub”), pursuant to which, on the terms and subject to the conditions set…
Open exhibit ↗EX-4.3 6 d128802dex43.htm EX-4.3 EX-4.3 Exhibit 4.3 EIGHTH SUPPLEMENTAL INDENTURE THIS EIGHTH SUPPLEMENTAL INDENTURE (this “Eighth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of January 17, 2018 (the “Base Indenture”), and the Fourth Supplemental Indenture, dated as of March 1, 2023 (the “Fourth Supplemental Indenture”, together with the Base Indenture, the “2030 Notes Indenture”) providing for the issuance of the 2.0% Convertible Senior Notes due 2030 (the “Notes”); WHEREAS, the Company entered into that certain Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among the Company, Abbott Laboratories, an Illinois corporation (“Abbott”), and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott (“Merger Sub”), pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with an…
Open exhibit ↗EX-4.4 7 d128802dex44.htm EX-4.4 EX-4.4 Exhibit 4.4 NINTH SUPPLEMENTAL INDENTURE THIS NINTH SUPPLEMENTAL INDENTURE (this “Ninth Supplemental Indenture”) dated as of March 23, 2026 between Exact Sciences Corporation, a Delaware corporation, as issuer (the “Company”) and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”). W I T N E S S E T H : WHEREAS, the Company and the Trustee are parties to an Indenture, dated as of January 17, 2018 (the “Base Indenture”), and the Fifth Supplemental Indenture, dated as of April 17, 2024 (the “Fifth Supplemental Indenture”, together with the Base Indenture, the “2031 Notes Indenture”) providing for the issuance of the 1.75% Convertible Senior Notes due 2031 (the “Notes”); WHEREAS, the Company entered into that certain Agreement and Plan of Merger, dated as of November 19, 2025 (the “Merger Agreement”), by and among the Company, Abbott Laboratories, an Illinois corporation (“Abbott”), and Badger Merger Sub I, Inc., a Delaware corporation and a wholly owned subsidiary of Abbott (“Merger Sub”), pursuant to which, on the terms and subject to the conditions set forth in the Merger Agreement, Merger Sub merged with and i…
Open exhibit ↗